Related Experiment Video
Updated: Feb 24, 2026
07:44
Identifying Protein-protein Interaction Sites Using Peptide Arrays
Published on: November 18, 2014
18.6K
Reverse Phase Protein Arrays and Drug Discovery.
Kenneth G Macleod1, Bryan Serrels1, Neil O Carragher2
1Cancer Research UK Edinburgh Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Crewe Road South, Edinburgh, EH4 2XR, UK.
Methods in Molecular Biology (Clifton, N.J.)
|August 16, 2017
Summary
Reverse Phase Protein Arrays (RPPA) offer sensitive antibody-based protein quantification. This study details protocols and compares two RPPA platforms for drug discovery applications.
Area of Science:
- Biochemistry
- Proteomics
- Molecular Biology
Background:
- Reverse Phase Protein Arrays (RPPA) are a sensitive antibody-based proteomic technique.
- RPPA allows for simultaneous quantification of protein abundance and post-translational modifications across numerous samples.
Purpose of the Study:
- To provide detailed protocols for RPPA.
- To compare two common RPPA platform technologies based on distinct protein-binding substrates.
- To evaluate the advantages and limitations of each platform for drug discovery.
Main Methods:
- Development and execution of RPPA protocols on two different protein-binding substrates.
- Utilizing two prevalent RPPA platform technologies.
- Comparative analysis of platform performance in drug discovery contexts.
Main Results:
- Detailed protocols for RPPA implementation are presented.
- A comparative analysis highlights the strengths and weaknesses of each RPPA platform.
- The study identifies key considerations for selecting an RPPA platform in drug discovery.
Conclusions:
- RPPA is a powerful tool for high-throughput proteomic analysis.
- The choice of RPPA platform and substrate impacts experimental outcomes.
- Understanding platform-specific characteristics is crucial for successful drug discovery applications using RPPA.
